NCT04434469View on ClinicalTrials.gov

A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 8, 2020

Primary Completion Date

February 23, 2022

Study Completion Date

February 23, 2022

Conditions
Refractory Multiple MyelomaRelapsed Multiple Myeloma
Interventions
DRUG

RO7297089

RO7297089 will be given via intravenous (IV) infusion

Trial Locations (10)

2100

Rigshospitalet, København Ø

2139

Concord Repatriation General Hospital, Concord

2170

LIVERPOOL HOSPITAL; HAEMATOLOGY; Ingham Institute for Medical Research, Liverpool

3000

UZ Leuven, Leuven

3002

Peter Mac Callum Cancer Center, East Melbourne

3065

St. Vincent's Hospital Melbourne, Fitzroy

5000

Royal Adelaide Hospital; Haematology Clinical Trials, Adelaide

7100

Vejle Sygehus; Onkologisk Afdeling, Vejle

9000

UZ Gent, Ghent

0450

Oslo Universitetssykehus HF; Ullevål sykehus, Oslo

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY